AR056453A1 - Composiciones con estrogeno y metodos terapeuticos para su uso - Google Patents

Composiciones con estrogeno y metodos terapeuticos para su uso

Info

Publication number
AR056453A1
AR056453A1 ARP060103508A ARP060103508A AR056453A1 AR 056453 A1 AR056453 A1 AR 056453A1 AR P060103508 A ARP060103508 A AR P060103508A AR P060103508 A ARP060103508 A AR P060103508A AR 056453 A1 AR056453 A1 AR 056453A1
Authority
AR
Argentina
Prior art keywords
composition
estrogenic compound
vulvovaginal
compositions
approximately
Prior art date
Application number
ARP060103508A
Other languages
English (en)
Inventor
Jonathan Bortz
Original Assignee
Drug Tech Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Drug Tech Corp filed Critical Drug Tech Corp
Publication of AR056453A1 publication Critical patent/AR056453A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0014—Skin, i.e. galenical aspects of topical compositions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/566—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol having an oxo group in position 17, e.g. estrone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/567—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in position 17 alpha, e.g. mestranol, norethandrolone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/24—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing atoms other than carbon, hydrogen, oxygen, halogen, nitrogen or sulfur, e.g. cyclomethicone or phospholipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0034—Urogenital system, e.g. vagina, uterus, cervix, penis, scrotum, urethra, bladder; Personal lubricants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/02—Drugs for genital or sexual disorders; Contraceptives for disorders of the vagina
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Endocrinology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Biophysics (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Dispersion Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

Una composicion farmacéutica comprende por lo menos un compuesto estrogénico, donde la composicion está adaptada para su aplicacion en una dosis unitaria a una superficie vulvovaginal y que tiene por lo menos una fase interna no lipoide y por lo menos una fase externa lipoide que es bioadhesiva a la superficie vulvovaginal, donde el por lo menos un compuesto estrogénico está presente en una cantidad de aproximadamente entre 5 y 1000mg de estradiol equivalente por dosis unitaria de la composicion, y al aplicar la composicion a la superficie vulvovaginal el por lo menos un compuesto estrogénico se libera a lo largo de un período de aproximadamente entre 3 horas y 3 días. La composicion es util para administracion vulvovaginal para tratar la vaginitis atrofica o un trastorno asociada con la misma, por ejemplo en una mujer menopáusica o posmenopásusica. Un método para tratar una condicion relacionada con hipoestrogenismo del aparato urogenital de una paciente femenina comprende la administracion intravaginal de por lo menos un compuesto estrogénico de acuerdo con un régimen de tratamiento en el cual una serie de composiciones del por lo menos un compuesto estrogénico que liberan una cantidad diaria que se incrementa progresivamente se administra a lo largo de un período de por lo menos aproximadamente 1 mes.
ARP060103508A 2005-08-12 2006-08-10 Composiciones con estrogeno y metodos terapeuticos para su uso AR056453A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US70766205P 2005-08-12 2005-08-12

Publications (1)

Publication Number Publication Date
AR056453A1 true AR056453A1 (es) 2007-10-10

Family

ID=37758140

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060103508A AR056453A1 (es) 2005-08-12 2006-08-10 Composiciones con estrogeno y metodos terapeuticos para su uso

Country Status (13)

Country Link
US (1) US20070036848A1 (es)
EP (1) EP1912623A2 (es)
JP (1) JP2009504667A (es)
KR (1) KR20080033400A (es)
CN (1) CN101351188A (es)
AR (1) AR056453A1 (es)
AU (1) AU2006280002A1 (es)
BR (1) BRPI0614625A2 (es)
CA (1) CA2617106A1 (es)
IL (1) IL189364A0 (es)
MX (1) MX2008001687A (es)
PE (1) PE20070329A1 (es)
WO (1) WO2007021805A2 (es)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101232869B (zh) * 2005-06-16 2016-03-02 沃纳奇尔科特有限责任公司 局部给药的凝胶组合物
EP1904028A1 (en) * 2005-06-16 2008-04-02 Warner Chilcott Company Inc. Estrogen compositions for vaginal administration
CN101249070B (zh) * 2008-04-02 2010-07-21 郑州大学 2-甲氧基雌二醇静脉纳米乳剂
ES2344673B1 (es) * 2008-08-07 2011-05-03 Italfarmaco, S.A. Uso de estriol en la preparacion de una formulacion farmaceutica parael tratamiento de atrofia vaginal en mujeres con riesgo de potologiatumoral.
ES2344675B1 (es) 2008-12-19 2011-04-28 Italfarmaco, S.A. Uso de estriol en la preparacion de una formulacion farrmaceutica para el tratamiento de atrofia vaginal en mujeres con riesgo de patologiacardiovascular.
US10568891B2 (en) * 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
CN103394127A (zh) * 2013-08-02 2013-11-20 苏州市马尔泰新材料有限公司 一种含有中西医药的阴道模具材料
CN103394132A (zh) * 2013-08-02 2013-11-20 苏州市马尔泰新材料有限公司 一种制备阴道模具的材料
CN103394129A (zh) * 2013-08-02 2013-11-20 苏州市马尔泰新材料有限公司 一种制备模具的材料
CN103394128A (zh) * 2013-08-02 2013-11-20 苏州市马尔泰新材料有限公司 一种含有川芎的模具材料
CN103445892A (zh) * 2013-08-02 2013-12-18 苏州市马尔泰新材料有限公司 一种含有甲酯树脂和雌酚的阴道模具
CN103405810A (zh) * 2013-08-02 2013-11-27 苏州市马尔泰新材料有限公司 一种含有甲基丙烯酸甲酯树脂的阴道模具
CN103393488A (zh) * 2013-08-02 2013-11-20 苏州市马尔泰新材料有限公司 一种含有雌三醇的阴道模具
CN103405294A (zh) * 2013-08-02 2013-11-27 苏州市马尔泰新材料有限公司 一种含有雌酚的阴道模具
CN103431930A (zh) * 2013-08-02 2013-12-11 苏州市马尔泰新材料有限公司 一种含有甲酯树脂的阴道模具
CN103393489A (zh) * 2013-08-02 2013-11-20 苏州市马尔泰新材料有限公司 一种含有雌二醇的阴道模具
CN103357074A (zh) * 2013-08-02 2013-10-23 苏州市马尔泰新材料有限公司 一种缓释型制备模具的材料
CN103394130A (zh) * 2013-08-13 2013-11-20 苏州市马尔泰新材料有限公司 一种含有雌酚和川芎的模具材料
RU2713888C2 (ru) * 2013-10-10 2020-02-10 Терапьютиксмд, Инк. Фармацевтические составы и способы на основе эстрадиола для интравагинального введения
WO2015138668A1 (en) * 2014-03-12 2015-09-17 Warner Chilcott Company, Llc Low-dose estradiol cream
WO2017000080A1 (zh) * 2015-06-30 2017-01-05 上海交通大学 Estrone在制备抗卵巢癌和/或乳腺癌产品中的应用
SG11201809440PA (en) * 2016-05-02 2018-11-29 T & A Pharma Pty Ltd Compositions for the treatment of chronic vulval and perineal pain and symptoms and conditions associated therewith
SE1750680A1 (en) * 2017-05-30 2018-12-01 Peptonic Medical Ab Composition for treating or preventing climacteric disorders

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4436738A (en) * 1982-03-15 1984-03-13 Mead Johnson & Company Stabilized estradiol cream composition
US4551148A (en) * 1982-09-07 1985-11-05 Kv Pharmaceutical Company Vaginal delivery systems and their methods of preparation and use
US5266329A (en) * 1985-10-31 1993-11-30 Kv Pharmaceutical Company Vaginal delivery system
FR2739559B1 (fr) * 1995-10-05 1997-11-28 Innothera Lab Sa Gel pour hormonotherapie locale de la secheresse vaginale
FR2739558B1 (fr) * 1995-10-05 1997-11-28 Innothera Lab Sa Forme galenique unitaire pour hormonotherapie locale de la secheresse vaginale
US20040234606A1 (en) * 1997-09-12 2004-11-25 Levine Howard L. Localized vaginal delivery without detrimental blood levels
US5877216A (en) * 1997-10-28 1999-03-02 Vivus, Incorporated Treatment of female sexual dysfunction
US7018992B2 (en) * 2000-12-15 2006-03-28 Novo Nordisk A/S Hormone composition
US6899890B2 (en) * 2002-03-20 2005-05-31 Kv Pharmaceutical Company Bioadhesive drug delivery system
ES2237298B1 (es) * 2003-07-16 2006-11-01 Italfarmaco, S.A. Formulaciones mucoadhesivas semisolidas.
WO2005027807A1 (en) * 2003-09-19 2005-03-31 Drugtech Corporation Pharmaceutical delivery system
GB0405406D0 (en) * 2004-03-10 2004-04-21 Edko Pazarlama Tanitim Ltd Sti Anti-vaginitis compositions
US20060040904A1 (en) * 2004-08-17 2006-02-23 Ahmed Salah U Vaginal cream compositions, kits thereof and methods of using thereof
US20060183724A1 (en) * 2005-02-03 2006-08-17 Diliberti Charles E Compositions of unconjugated estrogens and methods for their use
WO2006127057A1 (en) * 2005-05-24 2006-11-30 Lyle Corporate Drvelopment, Inc. Non-systematic vaginal administration of estrogen and an androgen for the treatment of sexual dysfunction

Also Published As

Publication number Publication date
CN101351188A (zh) 2009-01-21
AU2006280002A1 (en) 2007-02-22
EP1912623A2 (en) 2008-04-23
WO2007021805A3 (en) 2007-08-09
US20070036848A1 (en) 2007-02-15
MX2008001687A (es) 2008-02-19
BRPI0614625A2 (pt) 2011-04-12
WO2007021805A2 (en) 2007-02-22
IL189364A0 (en) 2008-06-05
PE20070329A1 (es) 2007-03-29
JP2009504667A (ja) 2009-02-05
KR20080033400A (ko) 2008-04-16
CA2617106A1 (en) 2007-02-22

Similar Documents

Publication Publication Date Title
AR056453A1 (es) Composiciones con estrogeno y metodos terapeuticos para su uso
CO6251259A2 (es) Formulaciones farmaceuticas de estriol en baja dosis
AR049985A1 (es) Tratamiento de combinacion para enfermedades malignas no hematologicas
MXPA06012960A (es) Administracion transdermal de ficotoxinas.
BR9808888A (pt) Formas de dosagem e método de melhorar disfunção erétil masculina
CO7101246A2 (es) Compuesto de carbamato y preparación y uso de los mismos
CO6150188A2 (es) Uso de teencteplasa para tratar un ictus isquemico agudo
AR063109A1 (es) Terapias topicas para la mucositis oral y otras afecciones
GB2475013A (en) Dosages for menstrual suppression, contraception, and hormone replacement therapy, and methods of administrating same
CO5640120A2 (es) Formulacion y metodods para el tratamiento de trombocitemia
JP2004507496A5 (es)
NZ617397A (en) Pth-containing therapeutic/prophylactic agent for osteoporosis, characterized in that pth is administered once a week at unit dose of 100 to 200 units
AR048318A1 (es) Formulaciones de matriz orales que comprenden licarbazepina
AR046036A1 (es) Composiciones de risedronato y metodos para su uso
CO5190664A1 (es) Terapia de combinacion para el tratamiento de migrana administracion de un receptor 5ht, cafeina y un inhibidor de ciclooxigenasa-2
CR8010A (es) Regimenes de contraceptivos transdermicos extendidos
MX2021013285A (es) Uso de cannabidiol en el tratamiento del complejo de esclerosis tuberosa.
PE20120956A1 (es) Composicion farmaceutica que contiene buprenorfina y nalmefeno
WO2008051527A3 (en) Sustained release of agents for localized pain management
MX2010009578A (es) Metodos para incrementar el espesor epidermico de la piel mediante la administracion topica de un compuesto de vitamina d que contiene 19-nor.
AR092719A1 (es) Metodo y composicion para el tratamiento de ectoparasitos
AR063712A1 (es) Tratamiento del dolor usando satraplatino
MD3381G2 (ro) Metodă de tratament al parotiditei cronice la copii
WO2003059284A3 (en) Composition and method for inhibiting hypersensitivity
MD2827G2 (ro) Metodă de profilaxie a hiperplaziilor dishormonale ale glandei mamare

Legal Events

Date Code Title Description
FB Suspension of granting procedure